Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

2008100 citationsJournal Articlegreen Open Access

Authors

Claire Bonfils · Pyrogenesis (Canada)

Ann Kalita · Pyrogenesis (Canada)

Marja Dubay · Pyrogenesis (Canada)

Lillian L. Siu · Princess Margaret Cancer Centre

Michael A. Carducci · Sidney Kimmel Comprehensive Cancer Center

Gregory K. Reid · Pyrogenesis (Canada)

Robert E. Martell

Abstract

This study shows that MGCD0103 has sustained pharmacodynamic effects that can be monitored both in vitro and in vivo with a cell-based HDAC enzyme assay.

Topics & Keywords

Histone Deacetylase Inhibitors Research Protein Degradation and Inhibitors Adenosine and Purinergic Signaling

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 14, Issue 11, pp. 3441-3449

DOI: 10.1158/1078-0432.ccr-07-4427

Field-Weighted Citation Impact: 3.03